Literature DB >> 16258329

Stability of transmitted drug-resistant HIV-1 species.

Patricia A Cane1.   

Abstract

PURPOSE OF REVIEW: The proportion of patients showing primary infection with HIV-1 that are already resistant to antiviral drugs has been steadily increasing. Such resistance is known to compromise therapy response. Most patients, however, are not diagnosed during their incident infection and, until recently, it was not known for how long resistant virus can be detected following infection. This article reviews reports on the stability of transmitted resistance in the absence of therapy. RECENT
FINDINGS: It has now been shown that many resistance-associated mutations can persist for a considerable time following transmission in the absence of treatment and that such resistance can be further transmitted.
SUMMARY: Since transmitted resistance can be detected years after infection, it is now worthwhile carrying out resistance tests on newly diagnosed patients in which it is known that the level of transmitted resistance in the population warrants such testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258329     DOI: 10.1097/01.qco.0000191506.10363.e1

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

1.  Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Authors:  Mian-Er Cong; Ae S Youngpairoj; Qi Zheng; Wutyi Aung; James Mitchell; Elizabeth Sweeney; Debra L Hanson; R Michael Hendry; Charles Dobard; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Authors:  Virginie Supervie; J Gerardo García-Lerma; Walid Heneine; Sally Blower
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 5.  Epidemiology of human immunodeficiency virus in the United States.

Authors:  Susan Hariri; Matthew T McKenna
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

6.  Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains.

Authors:  J M Kitayimbwa; J Y T Mugisha; R A Saenz
Journal:  Theor Popul Biol       Date:  2016-08-20       Impact factor: 1.570

7.  Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana.

Authors:  Dorcas Maruapula; Iain J MacLeod; Sikhulile Moyo; Rosemary Musonda; Kaelo Seatla; Kesaobaka Molebatsi; Melvin Leteane; Max Essex; Simani Gaseitsiwe; Christopher F Rowley
Journal:  AAS Open Res       Date:  2021-05-07

8.  The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

Authors:  Jurgen Vercauteren; Koen Deforche; Kristof Theys; Michiel Debruyne; Luis Miguel Duque; Susana Peres; Ana Patricia Carvalho; Kamal Mansinho; Anne-Mieke Vandamme; Ricardo Camacho
Journal:  Retrovirology       Date:  2008-02-01       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.